Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study
Bijal Shah(Boston College), Roch Houot(Inserm), Kristen M. O’Dwyer(University of Rochester Medical Center), Patrick J. Stiff(Loyola University Medical Center), Martha Arellano(Memorial Sloan Kettering Cancer Center), Mehrdad Abedi(UC Davis Comprehensive Cancer Center), Deepa Jeyakumar(Dana-Farber Cancer Institute), Lang Zhou(Kite (United States)), Gary J. Schiller(Fred Hutch Cancer Center), Thibaut Leguay(Centre Hospitalier Universitaire de Bordeaux), Olalekan O. Oluwole(Vanderbilt University), Jinghui Dong(Chinese PLA General Hospital), Monique C. Minnema(University Medical Center Utrecht), Maria R. Baer(University of Maryland, Baltimore), Aaron C. Logan(University of California, San Francisco), Ryan D. Cassaday(University of Washington), Nicolas Boissel(Inserm), Dimitrios Tzachanis(Dana-Farber Cancer Institute), Behzad Kharabi Masouleh(Erytech Pharma (France)), Daniel J. DeAngelo(Dana-Farber Cancer Institute), Armin Ghobadi(Washington University in St. Louis), William G. Wierda(University of Maryland, Baltimore), Michael R. Bishop(University of Chicago), Yi Lin, Max S. Topp(Universitätsklinikum Würzburg), Jae H. Park(Memorial Sloan Kettering Cancer Center), Sabina Adhikary(Kite (United States)), Marion Subklewe(LMU Klinikum), Imi Faghmous(Kite (United States)), Petra Schuberth(Kite (United States))
Cited by 78
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
|Science Translational Medicine|2014|2.5k